Waqas Ghumman, MD
Advanced Heart Failure and Transplant Cardiology · Atlantis, FLNPI 1619931516
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $238,128 of the $276,023 with a category attached, or 86.3%. 33 manufacturers reported payments, led by Abiomed at 45.4% of the total. Reporting peaked in 2019 at $88,966 and has fallen 87.8% since, to $10,824 in 2025. Among advanced heart failure and transplant cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $477.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$125K
- Boehringer Ingelheim$54K
- Novartis$49K
- AstraZeneca$20K
- Lilly USA, LLC$16K
- Abbott$6K
- plus $6K from 27 others
Across 1 payment — averaging $19,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
What the payments were for
- Consulting fees$3,3001%
- Speaking & faculty fees$238,12886%
- Travel & lodging$16,4156%
- Food & beverage$17,9907%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 143 | $125,245 |
| Boehringer Ingelheim | 65 | $54,231 |
| Novartis | 67 | $48,916 |
| AstraZeneca | 49 | $19,639 |
| Lilly USA, LLC | 16 | $15,938 |
| Abbott | 67 | $6,225 |
| Pfizer | 12 | $926 |
| Actelion Pharmaceuticals US, Inc. | 25 | $915 |
| United Therapeutics Corporation | 24 | $701 |
| Cvrx, Inc. | 8 | $386 |
| Impulse Dynamics (USA) Inc. | 5 | $324 |
| Bayer | 14 | $289 |
| Kestra Medical Technology Services, Inc. | 5 | $268 |
| Medtronic(2 entities) | 9 | $242 |
| Merck | 7 | $203 |
| Alnylam Pharmaceuticals Inc. | 9 | $180 |
| Boston Scientific | 4 | $176 |
| E.r. Squibb & Sons, L.L.C. | 8 | $167 |
| Edwards Lifesciences | 3 | $159 |
| Amgen | 6 | $141 |
| Akcea Therapeutics, Inc. | 5 | $118 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $115 |
| Biotronik Inc. | 1 | $101 |
| Novo Nordisk | 3 | $91 |
| Bridgebio Pharma, Inc. | 4 | $91 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Vifor Pharma, Inc. | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| Biosense Webster, Inc. | 1 | $29 |
| Endotronix, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Sobi, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$121,694
- JARDIANCE$65,176
- ENTRESTO$47,775
- FARXIGA$19,101
- Mitra Clip system$4,438
- VYNDAQEL$700
- Barostim Neo System$276
- CardioMEMS HF System$162
- MitraClip System$128
- OPTIMIZER SMART SYSTEM$119
- Edwards SAPIEN 3 Transcatheter Heart Valve$114
- UPTRAVI$112
- OPSUMIT$112
- REMODULIN$111
- Assure WCD$107
- Orsiro Mission$101
How this compares
$276,023 in reported general payments places this provider in the 90th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 75 | $1,813,236 |
| VyndaqelTafamidis Meglumine | 11 | $337,396 |
| CamzyosMavacamten | 15 | $124,283 |
| EntrestoSacubitril/Valsartan | 74 | $92,446 |
| JardianceEmpagliflozin | 73 | $67,461 |
| EliquisApixaban | 39 | $33,300 |
| FarxigaDapagliflozin Propanediol | 18 | $19,374 |
| XareltoRivaroxaban | 11 | $11,606 |
| Sildenafil Citrate | 11 | $2,628 |
| Metoprolol Succinate | 68 | $872 |
| Bumetanide | 32 | $795 |
| Ezetimibe | 22 | $785 |
| Torsemide | 25 | $595 |
| Spironolactone | 99 | $588 |
| Digoxin | 29 | $486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $926 | $2,183,932125 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $167 | $124,28315 claims |
| NovartisEntresto | $48,916 | $92,44674 claims |
| Boehringer IngelheimJardiance | $54,231 | $67,46173 claims |
| AstraZenecaFarxiga | $19,639 | $19,37418 claims |
| Johnson & JohnsonXarelto | $19 | $11,60611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Atlantis
- Sajid MirzaAtlantis$10K
- Tiffany Graham-MooreAtlantis$988
- Kelly McCantsWinter Park$445K
- Naveen BellamOrlando$414K
- Phillip HabibDelray Beach$305K
- David SnipeliskyWeston$250K
- Elsy NavasNaples$234K
- David BaranWeston$116K
- Rohan GoswamiJacksonville$112K
- Tara Hrobowski-BlackmanLargo$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.